Familial microscopic hematuria (FMH) is associated with a genetically heterogeneous group of conditions including the collagen-IV nephropathies, the heritable C3/CFHR5 nephropathy and the glomerulopathy with fibronectin deposits. The clinical course varies widely, ranging from isolated benign familial hematuria to end-stage renal disease (ESRD) later in life. We investigated 24 families using next generation sequencing (NGS) for 5 genes: COL4A3, COL4A4, COL4A5, CFHR5 and FN1. In 17 families (71%), we found 15 pathogenic mutations in COL4A3/ A4/A5, 9 of them novel. In 5 families patients inherited classical AS with hemizygous X-linked COL4A5 mutations. Even more patients developed later-onset Alport-related nephropathy having inherited heterozygous COL4A3/A4 mutations that cause thin basement membranes. Amongst 62 heterozygous or hemizygous patients, 8 (13%) reached ESRD, while 25% of patients with heterozygous COL4A3/A4 mutations, aged >50-years, reached ESRD. In conclusion, COL4A mutations comprise a frequent cause of FMH. Heterozygous COL4A3/A4 mutations predispose to renal function impairment, supporting that thin basement membrane nephropathy is not always benign. The molecular diagnosis is essential for differentiating the X-linked from the autosomal recessive and dominant inheritance. Finally, NGS technology is established as the gold standard for the diagnosis of FMH and associated collagen-IV glomerulopathies, frequently averting the need for invasive renal biopsies.
| INTRODUCTION
Familial microscopic hematuria (FMH) is a common presenting feature of glomerular disease and it can be associated with later progression to proteinuria and reduced glomerular filtration rate (GFR), depending on the specific disease or gene at fault. During the past 3 decades the correlation between molecular genetics and hematuria of glomerular origin has been well described. Six genes (COL4A3, COL4A4, COL4A5, CFHR5, MYH9, FN1) have been identified, which when mutated cause hereditary forms of microscopic hematuria (MH). 1 In most cases mutations are found in COL4A3, COL4A4 or COL4A5 genes that code for the respective alpha chains of the trimeric collagen IV, the most important structural component of the glomerular basement membrane (GBM).
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Glomerular MH is the earliest presenting sign in males with AS and hemizygous mutations in the X-linked COL4A5 gene and in males or females with autosomal recessive AS (ARAS) who inherit homozygous or compound heterozygous mutations in the COL4A3 or COL4A4 genes. Glomerular MH is also the cardinal presenting finding in patients with thin basement membranes, a condition known with the descriptive term of thin basement membrane nephropathy (TBMN), which has an estimated population prevalence of 0.3%-1%.
About 40%-50% of these patients inherit heterozygous mutations in either of the COL4A3/A4 genes, thus actually representing the heterozygous carriers of the ARAS. [5] [6] [7] Most patients with AS will progress to end-stage renal disease (ESRD) at some point in their early life, usually before the age of 30, while in patients with heterozygous COL4A3/A4 mutations the long-term clinical outcome is largely unpredictable. hypertension and a variable rate of GFR decline, up to ESRD. They are rarely associated with hearing loss. [9] [10] [11] [12] Work on the same GreekCypriot cohort linked COL4A3/A4 heterozygous mutations with a severe outcome, usually after the fifth decade of life due to focal segmental glomerulosclerosis (FSGS). 10, 13 In fact, it is now well clarified that patients with heterozygous mutations in the COL4A3/A4 genes can be misdiagnosed with hereditary FSGS. 8, 14, 15 Consequently, many patients with thin basement membranes follow a clinical course reminiscent to a milder or later-onset Alport-related nephropathy (LOAN).
Herewith, we aimed at establishing the frequency of mutations in patients of 24 families from Greece presenting with FMH, most of them originating from the island of Crete. The molecular investigation was performed with the use of high throughput next generation sequencing (NGS). We found 15 clearly pathogenic mutations, 9 novel, in 17 families.
| MATERIALS AND METHODS

| Patients and families
We studied 24 Greek families presenting with glomerular FMH that were consecutively referred to our centers. They included 237 subjects, of whom 177 were affected patients. DNA was available for 121 patients.
Inclusion criteria required that all families had a minimum of 3 affected subjects with isolated MH or MH plus proteinuria and reduced GFR.
Other non-glomerular causes of hematuria were excluded. Renal biopsies were available for patients in 14 of 24 (58.8%) families. In the participating clinical units, biopsies are not routinely performed in the presence of isolated MH. Of the 14 families 9 with available biopsies had at least 1 biopsy that showed thin membranes on electron microscope (EM).
Two out of these 9 also had signs of AS and 4 had additional signs of FSGS. For the remaining families, EM study was not available, but a number of them had evidence of FSGS on light microscopy. In 5 families, 1 or more patients had hearing loss.
All clinical and biological material was accessible through the University of Cyprus Biobank. 16 This research project was approved by the Cyprus National Bioethics Committee. The oligonucleotide sequences were adopted from previous publications. 10 Sanger DNA re-sequencing or restriction enzymes were used for examination of additional family members and healthy controls ( 
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Our NGS gene panel included also CFHR5 and FN1 but no pathogenic mutations were detected in either of them. CFHR5 is included because a mutation of exon 2-3 duplication is endemic among Cypriots, where our lab is located. 23 FN1 is included because when mutated, it is a known rare cause of FMH. 24 None of the 9 novel missense mutations was present in any of at least 35 normal controls, nor were they included in mutation databases, including the HGMD Professional, LOVD and ARUP. Certain families are quite extended; nonetheless DNA was not available from all affected individuals. Important findings in specific families are described below and in Tables 2 and 3 .
| Family CR-5316
COL4A4-p.G948Dfs2* (c.2843delG) was found in homozygosity in . In silico analysis indicated that it is pathogenic (Table 1) . Interestingly, in the same family, variant COL4A4-p.P222L was identified in 2 individuals, mother and daughter. Reportedly, the mother, who also carries the pathogenic mutation COL4A4-p.G948Dfs2* in trans, is most probably a rare polymorphism, unlikely to be pathogenic.
| Families CR-5408 and CR-5424
In Cretan families CR-5408 and CR-5424 ( Figure 1A ,B) mutations COL4A4-p.G774R and COL4A4-p.G1465D were found in cis configuration in 5 out of the 6 patients. One patient in family CR-5408 carries only the COL4A4-p.G774R mutation (previously reported by, 25 ) most probably due to a recombination event. COL4A4-p.G1465D was reported previously as a probably damaging variant. 26 This suggests the primary mutation is COL4A4-p.G774R and that COL4A4-p.G1465D is either neutral or has a milder effect, although this is a hypothesis to be tested in the future. In silico analysis is highly predictive for it being a pathogenic mutation, but for now it remains as VUS ( Table 1) . A biopsy was available from patient IV:2 (MH plus proteinuria at age 19 years),
showing thin basement membranes and focal sites with effacement of podocyte foot processes, in EM (Figure 2A,B) . Biopsy was available from patient IV:4 of family CR-5424 ( Figure 2C) showing FSGS, but unfortunately EM analysis was not available.
| Other families studied
Overall, in this study there was variable clinical information for 62 patients (24 male/38 female) at ages ranging from 16 to 81 years (Tables 2 and 3 ). All mutations identified were invariably associated with MH, while 11 of 42 (26%) of patients with autosomal mutations in COL4A3/A4, had added proteinuria without renal impairment and another 9/ of 42 (21%) had progressed to kidney function decline. Of Table 3 ). Also hearing loss was evident in a family with ARAS (family CR-5316; mutation COL4A4-p.G948Dfs2*), as well as in a patient with later-onset Alport related nephropathy (family GR-5499; mutation COL4A4-c.489 + 1G > C) ( Table 2 ).
Four patients in family GR-5473 presented exclusively with isolated MH. DNA was available from 2 of 4 patients that carried the mutation COL4A4-p.G143V. This mutation was previously found in a Greek-Cypriot unrelated family, perhaps as a recurrent event, although unknown genetic relationship cannot be excluded. 7 Each of mutations COL4A4-p.G748S, COL4A4-p.G774R and p.G1465D was a common finding between 2 seemingly unrelated families (Table 2 ) and probably represent founder effects on the island of Crete.
Altogether in this cohort (Tables 2 and 3 
| Phenocopies and incomplete penetrance
In each one of families GR-5310, CR-4244 and CR-4246 (mutations COL4A4-p.G1154V, COL4A5-p.G1036R and COL4A5-p.G743V, respectively), 1 phenocopy patient was identified as he presented with MH without carrying the respective mutation. 27 It is postulated that MH in these patients was due to a different cause. Contrastingly, In the same context, in family CR-4245 4 patients with MH do not carry the COL4A5-p.G365V mutation. We suspect that a second genetic etiology exists for these patients, because married-in individuals (DNA sample not available), also had MH ( Figure S1 ).
FIGURE 1 A and B, Pedigrees of families CR-5408 and CR-5424, with patients that carry 2 mutations, COL4A4-p.G774R and COL4A4-p.G1465D in cis. Judging from the fact that patient IV-2 in CR-5408 carries only mutation COL4A4-p.G774R, this is definitely pathogenic. Patients in these families had features of progressive disease, with biopsies featuring podocyte effacement and focal segmental glomerulosclerosis
| Coding non-pathogenic variants
We identified 51 polymorphic variants in the coding sequences of all 5 genes, with some of them being novel. Importantly, 39 were nonsynonymous, 1 of which involved a glycine in the 7S domain of COL4A3, p.G43R ( Workshop on AS at Gottingen, Germany, September 2015, it was discussed that the term TBMN, which in older literature is associated with familial benign hematuria, be negated and substituted by another terminology that would assist in consolidating that benign FMH is a misnomer. 33 Perhaps a better term to describe this condition, reminiscent to, but different from, classical AS, is autosomal dominant LOAN; it combines the name of Alport, which is a collagen IV nephropathy and the documented later age at onset of serious clinical symptoms and ultrastructural or extrarenal findings, if and when they occur. 34 
In a previous publication of our group we reported on 14 families with 54 patients who had solely manifested isolated FMH of glomerular origin and we found no mutations in the COL4 genes. Presumably these patients have inherited mutations in other, yet unknown, less deleterious genes. 7 This is another important reason that unknown genes, which when mutated may cause real isolated "benign" FMH, should be identified and studied. The molecular diagnosis will be indicative of the good prognosis of such patients. Patients from such families may be attracting the attention of researchers less frequently or with less interest and escape detailed genetic studies.
It is important to note that in the current study we focused on deciphering the mutation load of patients presenting glomerular FMH, with or without further progression. cell culture studies were also supportive. 42, 43 In the present cohort none of the patients examined carried a high risk modifier allele, most probably due to their low population frequency.
The ages at onset of ESRD in severe LOAN, usually in the 50s to 60s, appear to overlap with the ages at onset of ESRD in patients with milder X-linked AS, which sometimes may be misdiagnosed as TBMN, especially if the pedigree structure is misleading. [44] [45] [46] [47] [48] This certainly reflects the significant phenotypic heterogeneity, which can be partly attributed to the great allelic heterogeneity and partly to the likely role of genetic modifiers. Incomplete penetrance also was revealed in this cohort, as some family members remained healthy even though they have inherited the causative mutations. Phenocopies are occasional observations that require caution, especially if they happen to be the samples chosen for the molecular investigation, thus providing erroneous results of no mutation findings. 4. Equally important is to maintain and curate an in-house database of variants, pathogenic or neutral, for easy access during genetic investigations. It is the norm that every population has its own repertoire of DNA variants with varying frequencies, especially when serving island populations with strong founders such as the Cretan, the Cypriot and others.
5. The term "familial benign hematuria" should be avoided alltogether as a misnomer and an alternative term, perhaps "LaterOnset Alport-related Nephropathy" could be adopted to describe patients with thin basement membranes due to heterozygous COL4 mutations, with Alport-like adverse outcomes at older ages.
We understand that some authors who find also ultrastructural glomerular features pathognomonic for AS, or even extra renal manifestations (although very rare), prefer the use of autosomal dominant AS, although this term has not been globally accepted.
